gamma- linolenoyl- 3- eicosapentaenoylpropanediol
Networked: 1
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Neoplasms (Cancer)
05/01/1999
- " In short, a potentially desirable cytotoxic PUFA pattern can be achieved in host tissues and, in particular, in a human pancreatic tumor by providing GLA and EPA in the form GE-diol. " 05/01/1999
- " In tumor, liver, brain, kidney, plasma and fat tissue of mice fed GE diol, PUFA were increased over 25-fold, except for arachidonic acid (AA) levels, which were reduced or remained constant when compared to mice fed control corn oil diet. " 05/01/1999
- " Overall, these studies showed that: GE diol emulsions provide 640-fold higher doses of both GLA and EPA without causing hemolysis or adverse effects in the host mouse when compared to free PUFA infusions; GE diol is metabolized after oral or i.v. administration; tumor concentrations of GLA and EPA from the enterally administered diol were 4 to 13-fold higher than the in vitro cytotoxic levels; EPA, competes with AA and probably inhibits the activity of delta 5 desaturase without affecting the elongation of GLA in the host and tumor tissue; the change in PUFA profile modifies the substrates for eicosanoid synthesis. "
|
2. | Hemolysis
|
3. | Pancreatic Neoplasms (Pancreatic Cancer)
|
|
Related Drugs and Biologics
Related Therapies and Procedures